Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
about
MRI/MRS in neuroinflammation: methodology and applicationsVascular, glial, and lymphatic immune gateways of the central nervous systemActivation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous systemDevelopment of oral immunomodulatory agents in the management of multiple sclerosisNatalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosisLymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease?Revisiting the Mechanisms of CNS Immune Privilege.iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles.NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis.Kindlin-3 regulates integrin activation and adhesion reinforcement of effector T cells.Imaging Neuroinflammation - from Bench to Bedside.PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER.LRCH1 interferes with DOCK8-Cdc42-induced T cell migration and ameliorates experimental autoimmune encephalomyelitis.Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNSControl of alpha4beta7 integrin expression and CD4 T cell homing by the beta1 integrin subunit.Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report.Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin.Developing therapeutics for the treatment of multiple sclerosisTumor necrosis factor-induced neutrophil adhesion occurs via sphingosine kinase-1-dependent activation of endothelial {alpha}5{beta}1 integrin.Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases.Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologicallyNatalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.K+ channel alterations in the progression of experimental autoimmune encephalomyelitisdNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitisSuppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus.Challenges and opportunities: what we are learning from the clinical natalizumab experience.The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 miceAntigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.NLRP3 Inflammasome and MS/EAE.Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.Drug insight: using monoclonal antibodies to treat multiple sclerosis.Review part 2: Human herpesvirus-6 in central nervous system diseasesIntegrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding.Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis.Nuanced roles of cytokines in three major human brain disorders.A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet.
P2860
Q26771930-2C693AF1-BCEC-407A-8475-77C3AB7E6B24Q28071461-28C85D3E-2DD3-4771-8BF9-D2349C4A5BF1Q28250134-A74080D7-6123-46CA-BD57-447A9CF2468DQ28388704-DB711981-2859-46DA-9A0B-F477D291739DQ28484467-E8B8C759-F991-4D40-866F-1D6E2F9AD8F1Q30275974-14C79593-199F-4738-A685-26B39221BD7FQ30278584-1FD6050E-B2D8-474B-98A0-62BFC233C5BFQ30368046-73422FDC-DAB3-4C22-BD1C-C00915357ED3Q30519470-5E5D78B8-5D1A-4F11-A251-DB3DF2218BC1Q30552379-B2552BA7-AE92-45E0-BC02-255447C8EC94Q30881154-2910CAA0-A0A7-478F-9A4C-E4ACAA6FD067Q30987183-725AF81C-BF3C-4D1D-9767-2D9E561B6BBFQ33289411-B8BB74A2-827C-4953-8BE4-926C7761EE63Q33610978-6292B72F-20EF-4BD8-9823-B532D58645E9Q33670018-36FB50BB-38BF-46DB-906D-CF4D904361AFQ33700997-0C1D4C7B-E2FF-4CFA-A15F-188215E2BC74Q33782177-63486155-159A-43F3-A5C2-46356ECFEF01Q33946995-D4D07661-81F1-4F77-86E9-C6137A4F725CQ33947323-6CE5D714-536B-4280-8C03-EBE87B2DD681Q34784469-CAC7C070-BF97-4B83-B897-0B2D713A088CQ35928288-059F7367-23F7-4806-92DB-BCF06F31D153Q35939675-1936198B-607F-4994-BB7B-2D57CBD133C4Q36007543-8DD69A4E-C62A-42BB-9E5D-3263EB6B270DQ36085336-795C32EC-39B1-4171-B684-0AC2A5AC58B6Q36228518-A3E4FC94-975A-4D11-96BC-952B86AECA73Q36257198-6CC5878E-2E11-4EC1-BFA0-7CB2C96DA3A8Q36257833-1BB2F07C-9FBC-4A2B-9356-CB6A0DDEB2E6Q36327377-903CF926-C3E1-4FB9-9629-A885FAF38BA9Q36474344-7C9B2C45-7094-442F-B743-9DE92B664EF9Q36566053-38A574F4-3E84-40FB-92E2-8E088248A6E1Q36571347-6BF4BE5C-0FE3-4F6F-863E-DC4F19A69098Q36577212-89FDEF7B-9D55-4920-B389-BFD0EA1A3B49Q36592322-40245B61-F51D-4B51-B555-227A5CC48762Q36666787-EEB772F7-E1A8-430E-AC61-8DA4B57F57B4Q36688987-37253149-CF3B-4723-9F14-B888643F6519Q36767393-085E6678-415F-4341-8793-D275DFAB7CD2Q36914452-95DF737F-C9B2-4928-A3A1-10F064E63A87Q36955568-272FEC60-44A9-4B62-91FD-017248344DCDQ36960355-4F21B6F7-2DF0-4A7A-BD92-FC8E74678201Q36963194-81F6ADDF-777B-4272-8E50-843A300FBB86
P2860
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
@ast
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
@en
type
label
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
@ast
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
@en
prefLabel
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
@ast
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
@en
P2860
P356
P1476
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
@en
P2093
Lawrence Steinman
P2860
P2888
P304
P356
10.1038/NRD1752
P577
2005-06-01T00:00:00Z